ContraFect Corp - ESG Rating & Company Profile powered by AI
Other corporations in the scoring peer group for ContraFect Corp are displayed. If you are employed by ContraFect Corp and you wish to licence your ESG rating, please contact us. The webpage contains a free Sustainability assessment for ContraFect Corp.
ContraFect Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.6; made up of an environmental score of 2.7, social score of 3.2 and governance score of 8.0.
4.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 837 | Zentiva as | 4.7 | High |
| 837 | Zogenix Inc | 4.7 | High |
| 852 | ContraFect Corp | 4.6 | High |
| 852 | Canopy Growth Corp | 4.6 | High |
| 852 | Novavax Inc | 4.6 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does ContraFect Corp have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes ContraFect Corp disclose current and historical energy intensity?
Sign up for free to unlockDoes ContraFect Corp report the average age of the workforce?
Sign up for free to unlockDoes ContraFect Corp reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes ContraFect Corp disclose its ethnicity pay gap?
Sign up for free to unlockDoes ContraFect Corp disclose cybersecurity risks?
Sign up for free to unlockDoes ContraFect Corp offer flexible work?
Sign up for free to unlockDoes ContraFect Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes ContraFect Corp disclose the number of employees in R&D functions?
Sign up for free to unlockDoes ContraFect Corp conduct supply chain audits?
Sign up for free to unlockDoes ContraFect Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes ContraFect Corp conduct 360 degree staff reviews?
Sign up for free to unlockDoes ContraFect Corp disclose the individual responsible for D&I?
Sign up for free to unlockDoes ContraFect Corp disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes ContraFect Corp disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes ContraFect Corp disclose water use targets?
Sign up for free to unlockDoes ContraFect Corp have careers partnerships with academic institutions?
Sign up for free to unlockDid ContraFect Corp have a product recall in the last two years?
Sign up for free to unlockDoes ContraFect Corp disclose incidents of discrimination?
Sign up for free to unlockDoes ContraFect Corp allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas ContraFect Corp issued a profit warning in the past 24 months?
Sign up for free to unlockDoes ContraFect Corp disclose parental leave metrics?
Sign up for free to unlockDoes ContraFect Corp disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes ContraFect Corp disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes ContraFect Corp disclose the pay ratio of women to men?
Sign up for free to unlockDoes ContraFect Corp support suppliers with sustainability related research and development?
Sign up for free to unlockDoes ContraFect Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes ContraFect Corp reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs ContraFect Corp involved in embryonic stem cell research?
Sign up for free to unlockDoes ContraFect Corp disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes ContraFect Corp disclose its waste policy?
Sign up for free to unlockDoes ContraFect Corp report according to TCFD requirements?
Sign up for free to unlockDoes ContraFect Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes ContraFect Corp disclose energy use targets?
Sign up for free to unlockDoes ContraFect Corp disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes ContraFect Corp have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for ContraFect Corp
These potential risks are based on the size, segment and geographies of the company.
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.